Dr. Paul A. Hamlin

Dr. Paul A. Hamlin, MD, is a board-certified medical oncologist and member of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, where he has dedicated over two decades to the care of patients with Hodgkin lymphoma and non-Hodgkin lymphoma. Throughout his career at MSK, he has held numerous leadership roles, including Clinical Director of the Lymphoma Service, Chief of the Basking Ridge site, Acting Chief of the Lymphoma Service, and Medical Director of the David H. Koch Center for Cancer Care. His work reflects a commitment to building a collaborative, world-class environment that combines deep clinical expertise with access to cutting-edge research and specialized cancer care.

A central focus of Dr. Hamlin's clinical research is the development of novel therapies and dedicated treatment programs for older patients with lymphoma. As part of a multidisciplinary MSK team caring for patients aged 65 and older, he has worked to advance new treatment strategies for diffuse large B-cell lymphoma, mantle cell lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia/small lymphocytic leukemia. His research addresses the complex interplay between aging and cancer diagnosis, with ongoing efforts to create screening tools that identify patients at heightened risk for treatment side effects and to develop clinical trials specifically tailored to the older patient population. The shared goal of his team is to refine risk-adapted therapies that minimize side effects while maximizing effectiveness.

As a clinical researcher, Dr. Hamlin has served as principal investigator or co-principal investigator on more than 30 clinical trials. His investigative work explores novel biologic and immunotherapeutic agents for both Hodgkin and non-Hodgkin lymphoma, with phase I and II trials examining new antibody combinations, antibody drug conjugates, immunotoxins, and small molecule inhibitors. Through his sustained contributions to research, leadership, and patient care, Dr. Hamlin continues to shape advances in lymphoma treatment with a particular emphasis on improving outcomes for the most vulnerable patient populations.